Investigating obesity or overweight condition correlated to many co-morbidities
Conditions
Brief summary
Percent change in body weight from baseline after 36 weeks of treatment, Weight loss ≥ 5% from baseline after 36 weeks of treatment
Detailed description
Absolute change in body weight from baseline after 36 weeks of treatment, Percent and absolute change in body weight from baseline after 36 weeks of treatment, Weight loss ≥ 5% from baseline after 36 weeks of treatment, Weight loss ≥ 10% and ≥ 15% from baseline after 36 weeks of treatment, Prevalence, incidence and titres of ADAs to AZD9550 andAZD6234 in combination and as monotherapies after 36 weeks of treatment, To evaluate the safety and tolerability of AZD9550 and AZD6234 in combination compared with placebo and with monotherapy
Interventions
DRUGGLUCOSE
DRUGPlacebo for azd6234
DRUGAZD6234
DRUGCALCIUM CITRATE
DRUGCYCLIZINE
DRUGPlacebo for azd9550
DRUGGLUCAGON
DRUGCALCIUM CARBONATE
DRUGONDANSETRON
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change in body weight from baseline after 36 weeks of treatment, Weight loss ≥ 5% from baseline after 36 weeks of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Absolute change in body weight from baseline after 36 weeks of treatment, Percent and absolute change in body weight from baseline after 36 weeks of treatment, Weight loss ≥ 5% from baseline after 36 weeks of treatment, Weight loss ≥ 10% and ≥ 15% from baseline after 36 weeks of treatment, Prevalence, incidence and titres of ADAs to AZD9550 andAZD6234 in combination and as monotherapies after 36 weeks of treatment, To evaluate the safety and tolerability of AZD9550 and AZD6234 in combination compared with placebo and with monotherapy | — |
Countries
Germany
Outcome results
None listed